APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vascular Protective Agents

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Vascular Protective Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025193 pages

Choose your research edition.

Industry ResearchVascular Protective Agents Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Vascular Protective Agents Industry Growth and Trends Forecast to 2032129 pages · $3,450 USDMarket StructureGlobal Vascular Protective Agents Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vascular Protective Agents Market Outlook and Growth Opportunities 2026216 pages · $4,250 USDMarket Analysis & ForecastGlobal Vascular Protective Agents Market Analysis and Forecast 2026-2032210 pages · $4,950 USD

Market perspective

The global Vascular Protective Agents market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Vascular Protective Agents is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Vascular Protective Agents include Chongqing Huasen Pharmaceutical Co., Ltd., Yantai Dongcheng Pharmaceutical Group Co., Ltd., Xi'an Janssen Pharmaceutical Co., Ltd., Wuhan Aimin Pharmaceutical Co., Ltd., Tonghua Xindongri Pharmaceutical Co., Ltd., Sichuan Xieli Pharmaceutical Co., Ltd., Sichuan Feideli Pharmaceutical Co., Ltd., Shanxi Huakang Pharmaceutical Co., Ltd. and Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Vascular Protective Agents market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vascular Protective Agents and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vascular Protective Agents sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Vascular Protective Agents market size, projected growth trends, production technologies, key applications, and end-use industries.

Vascular Protective Agents Segment by Company

Chongqing Huasen Pharmaceutical Co., Ltd.

Yantai Dongcheng Pharmaceutical Group Co., Ltd.

Xi'an Janssen Pharmaceutical Co., Ltd.

Wuhan Aimin Pharmaceutical Co., Ltd.

Tonghua Xindongri Pharmaceutical Co., Ltd.

Sichuan Xieli Pharmaceutical Co., Ltd.

Sichuan Feideli Pharmaceutical Co., Ltd.

Shanxi Huakang Pharmaceutical Co., Ltd.

Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.

Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.

Mayinglong Pharmaceutical Group Co., Ltd.

Jilin Jinsheng Pharmaceutical Co., Ltd.

Hunan Yige Pharmaceutical Co., Ltd.

Hubei Keyi Pharmaceutical Co., Ltd.

Guangxi Hercules Pharmaceutical Co., Ltd.

Chengdu Yazhong Biopharmaceutical Co., Ltd.

Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.

STELLA

Stanex

Sebela Pharmaceuticals Inc.

Pfizer

Manus Aktteva Biopharma LLP

Hepac

Globela Pharma

Bioiberica

Advacare Pharma

Vascular Protective Agents Segment by Type

Diosmin (Citrus Flavonoids)

Polysaccharide Polysulfate

Complex Carrageenan Esters

Heparin

Aescin

Trexerutin

Vascular Protective Agents Segment by Application

Hospital

Clinic

Other

Vascular Protective Agents Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vascular Protective Agents market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vascular Protective Agents and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vascular Protective Agents.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Vascular Protective Agents market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Vascular Protective Agents manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Vascular Protective Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Vascular Protective Agents in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Vascular Protective Agents Industry Trends Table 2. Vascular Protective Agents Industry Drivers Table 3. Vascular Protective Agents Industry Opportunities and Challenges Table 4. Vascular Protective Agents Industry Restraints Table 5. Global Vascular Protective Agents Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Vascular Protective Agents Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Vascular Protective Agents Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Vascular Protective Agents Sales Market Share by Manufacturers Table 9. Global Vascular Protective Agents Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Vascular Protective Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Vascular Protective Agents Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Vascular Protective Agents Manufacturers, Product Type & Application Table 13. Global Vascular Protective Agents Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Vascular Protective Agents by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Diosmin (Citrus Flavonoids) Table 17. Major Manufacturers of Polysaccharide Polysulfate Table 18. Major Manufacturers of Complex Carrageenan Esters Table 19. Major Manufacturers of Heparin Table 20. Major Manufacturers of Aescin Table 21. Major Manufacturers of Trexerutin Table 22. Global Vascular Protective Agents Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Vascular Protective Agents Sales by Type (2021-2026) & (K Units) Table 24. Global Vascular Protective Agents Sales by Type (2027-2032) & (K Units) Table 25. Global Vascular Protective Agents Sales Market Share by Type (2021-2026) Table 26. Global Vascular Protective Agents Sales Market Share by Type (2027-2032) Table 27. Global Vascular Protective Agents Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 28. Global Vascular Protective Agents Revenue by Type (2021-2026) & (K Units) Table 29. Global Vascular Protective Agents Revenue by Type (2027-2032) & (K Units) Table 30. Global Vascular Protective Agents Revenue Market Share by Type (2021-2026) Table 31. Global Vascular Protective Agents Revenue Market Share by Type (2027-2032) Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Other Table 35. Global Vascular Protective Agents Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Vascular Protective Agents Sales by Application (2021-2026) & (K Units) Table 37. Global Vascular Protective Agents Sales by Application (2027-2032) & (K Units) Table 38. Global Vascular Protective Agents Sales Market Share by Application (2021-2026) Table 39. Global Vascular Protective Agents Sales Market Share by Application (2027-2032) Table 40. Global Vascular Protective Agents Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global Vascular Protective Agents Revenue by Application (2021-2026) & (K Units) Table 42. Global Vascular Protective Agents Revenue by Application (2027-2032) & (K Units) Table 43. Global Vascular Protective Agents Revenue Market Share by Application (2021-2026) Table 44. Global Vascular Protective Agents Revenue Market Share by Application (2027-2032) Table 45. Global Vascular Protective Agents Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Vascular Protective Agents Sales by Region (2021-2026) & (K Units) Table 47. Global Vascular Protective Agents Sales Market Share by Region (2021-2026) Table 48. Global Vascular Protective Agents Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global Vascular Protective Agents Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 52. North America Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 53. Europe Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 55. Europe Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa Vascular Protective Agents Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa Vascular Protective Agents Sales by Country (2027-2032) & (K Units) Table 62. Global Vascular Protective Agents Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Vascular Protective Agents Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Vascular Protective Agents Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Vascular Protective Agents Revenue Market Share by Region (2021-2026) Table 66. Global Vascular Protective Agents Revenue Market Share by Region (2027-2032) Table 67. Chongqing Huasen Pharmaceutical Co., Ltd. Company Information Table 68. Chongqing Huasen Pharmaceutical Co., Ltd. Business Overview Table 69. Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 71. Chongqing Huasen Pharmaceutical Co., Ltd. Recent Development Table 72. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Company Information Table 73. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview Table 74. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio Table 76. Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Development Table 77. Xi'an Janssen Pharmaceutical Co., Ltd. Company Information Table 78. Xi'an Janssen Pharmaceutical Co., Ltd. Business Overview Table 79. Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 81. Xi'an Janssen Pharmaceutical Co., Ltd. Recent Development Table 82. Wuhan Aimin Pharmaceutical Co., Ltd. Company Information Table 83. Wuhan Aimin Pharmaceutical Co., Ltd. Business Overview Table 84. Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 86. Wuhan Aimin Pharmaceutical Co., Ltd. Recent Development Table 87. Tonghua Xindongri Pharmaceutical Co., Ltd. Company Information Table 88. Tonghua Xindongri Pharmaceutical Co., Ltd. Business Overview Table 89. Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 91. Tonghua Xindongri Pharmaceutical Co., Ltd. Recent Development Table 92. Sichuan Xieli Pharmaceutical Co., Ltd. Company Information Table 93. Sichuan Xieli Pharmaceutical Co., Ltd. Business Overview Table 94. Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 96. Sichuan Xieli Pharmaceutical Co., Ltd. Recent Development Table 97. Sichuan Feideli Pharmaceutical Co., Ltd. Company Information Table 98. Sichuan Feideli Pharmaceutical Co., Ltd. Business Overview Table 99. Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 101. Sichuan Feideli Pharmaceutical Co., Ltd. Recent Development Table 102. Shanxi Huakang Pharmaceutical Co., Ltd. Company Information Table 103. Shanxi Huakang Pharmaceutical Co., Ltd. Business Overview Table 104. Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 106. Shanxi Huakang Pharmaceutical Co., Ltd. Recent Development Table 107. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information Table 108. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview Table 109. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 111. Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Development Table 112. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Company Information Table 113. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Business Overview Table 114. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 116. Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Recent Development Table 117. Mayinglong Pharmaceutical Group Co., Ltd. Company Information Table 118. Mayinglong Pharmaceutical Group Co., Ltd. Business Overview Table 119. Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio Table 121. Mayinglong Pharmaceutical Group Co., Ltd. Recent Development Table 122. Jilin Jinsheng Pharmaceutical Co., Ltd. Company Information Table 123. Jilin Jinsheng Pharmaceutical Co., Ltd. Business Overview Table 124. Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 125. Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 126. Jilin Jinsheng Pharmaceutical Co., Ltd. Recent Development Table 127. Hunan Yige Pharmaceutical Co., Ltd. Company Information Table 128. Hunan Yige Pharmaceutical Co., Ltd. Business Overview Table 129. Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 130. Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 131. Hunan Yige Pharmaceutical Co., Ltd. Recent Development Table 132. Hubei Keyi Pharmaceutical Co., Ltd. Company Information Table 133. Hubei Keyi Pharmaceutical Co., Ltd. Business Overview Table 134. Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 135. Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 136. Hubei Keyi Pharmaceutical Co., Ltd. Recent Development Table 137. Guangxi Hercules Pharmaceutical Co., Ltd. Company Information Table 138. Guangxi Hercules Pharmaceutical Co., Ltd. Business Overview Table 139. Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 140. Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 141. Guangxi Hercules Pharmaceutical Co., Ltd. Recent Development Table 142. Chengdu Yazhong Biopharmaceutical Co., Ltd. Company Information Table 143. Chengdu Yazhong Biopharmaceutical Co., Ltd. Business Overview Table 144. Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 145. Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 146. Chengdu Yazhong Biopharmaceutical Co., Ltd. Recent Development Table 147. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Company Information Table 148. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Business Overview Table 149. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 150. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio Table 151. Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Recent Development Table 152. STELLA Company Information Table 153. STELLA Business Overview Table 154. STELLA Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 155. STELLA Vascular Protective Agents Product Portfolio Table 156. STELLA Recent Development Table 157. Stanex Company Information Table 158. Stanex Business Overview Table 159. Stanex Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 160. Stanex Vascular Protective Agents Product Portfolio Table 161. Stanex Recent Development Table 162. Sebela Pharmaceuticals Inc. Company Information Table 163. Sebela Pharmaceuticals Inc. Business Overview Table 164. Sebela Pharmaceuticals Inc. Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 165. Sebela Pharmaceuticals Inc. Vascular Protective Agents Product Portfolio Table 166. Sebela Pharmaceuticals Inc. Recent Development Table 167. Pfizer Company Information Table 168. Pfizer Business Overview Table 169. Pfizer Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 170. Pfizer Vascular Protective Agents Product Portfolio Table 171. Pfizer Recent Development Table 172. Manus Aktteva Biopharma LLP Company Information Table 173. Manus Aktteva Biopharma LLP Business Overview Table 174. Manus Aktteva Biopharma LLP Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 175. Manus Aktteva Biopharma LLP Vascular Protective Agents Product Portfolio Table 176. Manus Aktteva Biopharma LLP Recent Development Table 177. Hepac Company Information Table 178. Hepac Business Overview Table 179. Hepac Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 180. Hepac Vascular Protective Agents Product Portfolio Table 181. Hepac Recent Development Table 182. Globela Pharma Company Information Table 183. Globela Pharma Business Overview Table 184. Globela Pharma Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 185. Globela Pharma Vascular Protective Agents Product Portfolio Table 186. Globela Pharma Recent Development Table 187. Bioiberica Company Information Table 188. Bioiberica Business Overview Table 189. Bioiberica Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 190. Bioiberica Vascular Protective Agents Product Portfolio Table 191. Bioiberica Recent Development Table 192. Advacare Pharma Company Information Table 193. Advacare Pharma Business Overview Table 194. Advacare Pharma Vascular Protective Agents Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 195. Advacare Pharma Vascular Protective Agents Product Portfolio Table 196. Advacare Pharma Recent Development Table 197. Key Raw Materials Table 198. Raw Materials Key Suppliers Table 199. Vascular Protective Agents Distributors List Table 200. Vascular Protective Agents Customers List Table 201. Research Programs/Design for This Report Table 202. Authors List of This Report Table 203. Secondary Sources Table 204. Primary Sources List of Figures Figure 1. Vascular Protective Agents Product Image Figure 2. Global Vascular Protective Agents Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vascular Protective Agents Market Size (2021-2032) & (US$ Million) Figure 4. Global Vascular Protective Agents Sales (2021-2032) & (K Units) Figure 5. Global Vascular Protective Agents Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Vascular Protective Agents Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Diosmin (Citrus Flavonoids) Image Figure 9. Polysaccharide Polysulfate Image Figure 10. Complex Carrageenan Esters Image Figure 11. Heparin Image Figure 12. Aescin Image Figure 13. Trexerutin Image Figure 14. Global Vascular Protective Agents Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Vascular Protective Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 16. Global Vascular Protective Agents Sales Market Share by Type (2021-2032) Figure 17. Global Vascular Protective Agents Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 18. Global Vascular Protective Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Vascular Protective Agents Revenue Market Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Other Image Figure 23. Global Vascular Protective Agents Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Vascular Protective Agents Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Vascular Protective Agents Sales Market Share by Application (2021-2032) Figure 26. Global Vascular Protective Agents Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global Vascular Protective Agents Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Vascular Protective Agents Revenue Market Share by Application (2021-2032) Figure 29. North America Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 31. U.S. Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 36. Germany Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 43. China Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa Vascular Protective Agents Sales Market Share by Country (2021-2032) Figure 51. Brazil Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile Vascular Protective Agents Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global Vascular Protective Agents Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Vascular Protective Agents Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Vascular Protective Agents Revenue (2021-2032) & (US$ Million) Figure 62. North America Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Vascular Protective Agents Revenue (2021-2032) & (US$ Million) Figure 64. Europe Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Vascular Protective Agents Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Vascular Protective Agents Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Vascular Protective Agents Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Vascular Protective Agents Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Diosmin (Citrus Flavonoids)
  • Polysaccharide Polysulfate
  • Complex Carrageenan Esters
  • Heparin
  • Aescin
  • Trexerutin
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chongqing Huasen Pharmaceutical Co., Ltd.
  • Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  • Xi'an Janssen Pharmaceutical Co., Ltd.
  • Wuhan Aimin Pharmaceutical Co., Ltd.
  • Tonghua Xindongri Pharmaceutical Co., Ltd.
  • Sichuan Xieli Pharmaceutical Co., Ltd.
  • Sichuan Feideli Pharmaceutical Co., Ltd.
  • Shanxi Huakang Pharmaceutical Co., Ltd.
  • Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  • Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  • Mayinglong Pharmaceutical Group Co., Ltd.
  • Jilin Jinsheng Pharmaceutical Co., Ltd.
  • Hunan Yige Pharmaceutical Co., Ltd.
  • Hubei Keyi Pharmaceutical Co., Ltd.
  • Guangxi Hercules Pharmaceutical Co., Ltd.
  • Chengdu Yazhong Biopharmaceutical Co., Ltd.
  • Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
  • STELLA
  • Stanex
  • Sebela Pharmaceuticals Inc.
  • Pfizer
  • Manus Aktteva Biopharma LLP
  • Hepac
  • Globela Pharma
  • Bioiberica
  • Advacare Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vascular Protective Agents Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vascular Protective Agents Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Vascular Protective Agents Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Vascular Protective Agents Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Vascular Protective Agents Market Dynamics
  1. 2.1 Vascular Protective Agents Industry Trends
  2. 2.2 Vascular Protective Agents Industry Drivers
  3. 2.3 Vascular Protective Agents Industry Opportunities and Challenges
  4. 2.4 Vascular Protective Agents Industry Restraints
3 Vascular Protective Agents Market by Manufacturers
  1. 3.1 Global Vascular Protective Agents Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Vascular Protective Agents Sales by Manufacturers (2021-2026)
  3. 3.3 Global Vascular Protective Agents Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Vascular Protective Agents Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Vascular Protective Agents Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Vascular Protective Agents Manufacturers, Product Type & Application
  7. 3.7 Global Vascular Protective Agents Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Vascular Protective Agents Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Vascular Protective Agents Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Vascular Protective Agents Tier 1, Tier 2, and Tier 3
4 Vascular Protective Agents Market by Type
  1. 4.1 Vascular Protective Agents Type Introduction
  2. 4.1.1 Diosmin (Citrus Flavonoids)
  3. 4.1.2 Polysaccharide Polysulfate
  4. 4.1.3 Complex Carrageenan Esters
  5. 4.1.4 Heparin
  6. 4.1.5 Aescin
  7. 4.1.6 Trexerutin
  8. 4.2 Global Vascular Protective Agents Sales by Type
  9. 4.2.1 Global Vascular Protective Agents Sales by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Vascular Protective Agents Sales by Type (2021-2032)
  11. 4.2.3 Global Vascular Protective Agents Sales Market Share by Type (2021-2032)
  12. 4.3 Global Vascular Protective Agents Revenue by Type
  13. 4.3.1 Global Vascular Protective Agents Revenue by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Vascular Protective Agents Revenue by Type (2021-2032)
  15. 4.3.3 Global Vascular Protective Agents Revenue Market Share by Type (2021-2032)
5 Vascular Protective Agents Market by Application
  1. 5.1 Vascular Protective Agents Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Vascular Protective Agents Sales by Application
  6. 5.2.1 Global Vascular Protective Agents Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Vascular Protective Agents Sales by Application (2021-2032)
  8. 5.2.3 Global Vascular Protective Agents Sales Market Share by Application (2021-2032)
  9. 5.3 Global Vascular Protective Agents Revenue by Application
  10. 5.3.1 Global Vascular Protective Agents Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Vascular Protective Agents Revenue by Application (2021-2032)
  12. 5.3.3 Global Vascular Protective Agents Revenue Market Share by Application (2021-2032)
6 Global Vascular Protective Agents Sales by Region
  1. 6.1 Global Vascular Protective Agents Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vascular Protective Agents Sales by Region (2021-2032)
  3. 6.2.1 Global Vascular Protective Agents Sales by Region (2021-2026)
  4. 6.2.2 Global Vascular Protective Agents Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Vascular Protective Agents Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Vascular Protective Agents Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Vascular Protective Agents Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Vascular Protective Agents Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Vascular Protective Agents Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Vascular Protective Agents Revenue by Region
  1. 7.1 Global Vascular Protective Agents Revenue by Region
  2. 7.1.1 Global Vascular Protective Agents Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Vascular Protective Agents Revenue by Region (2021-2026)
  4. 7.1.3 Global Vascular Protective Agents Revenue by Region (2027-2032)
  5. 7.1.4 Global Vascular Protective Agents Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Vascular Protective Agents Revenue (2021-2032)
  8. 7.2.2 North America Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Vascular Protective Agents Revenue (2021-2032)
  11. 7.3.2 Europe Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Vascular Protective Agents Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Vascular Protective Agents Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Vascular Protective Agents Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chongqing Huasen Pharmaceutical Co., Ltd.
  2. 8.1.1 Chongqing Huasen Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Chongqing Huasen Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chongqing Huasen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  6. 8.1.5 Chongqing Huasen Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
  8. 8.2.1 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Company Information
  9. 8.2.2 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Business Overview
  10. 8.2.3 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio
  12. 8.2.5 Yantai Dongcheng Pharmaceutical Group Co., Ltd. Recent Developments
  13. 8.3 Xi'an Janssen Pharmaceutical Co., Ltd.
  14. 8.3.1 Xi'an Janssen Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Xi'an Janssen Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Xi'an Janssen Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  18. 8.3.5 Xi'an Janssen Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Wuhan Aimin Pharmaceutical Co., Ltd.
  20. 8.4.1 Wuhan Aimin Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Wuhan Aimin Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Wuhan Aimin Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  24. 8.4.5 Wuhan Aimin Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Tonghua Xindongri Pharmaceutical Co., Ltd.
  26. 8.5.1 Tonghua Xindongri Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Tonghua Xindongri Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tonghua Xindongri Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  30. 8.5.5 Tonghua Xindongri Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Sichuan Xieli Pharmaceutical Co., Ltd.
  32. 8.6.1 Sichuan Xieli Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Sichuan Xieli Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sichuan Xieli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  36. 8.6.5 Sichuan Xieli Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Sichuan Feideli Pharmaceutical Co., Ltd.
  38. 8.7.1 Sichuan Feideli Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Sichuan Feideli Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sichuan Feideli Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  42. 8.7.5 Sichuan Feideli Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Shanxi Huakang Pharmaceutical Co., Ltd.
  44. 8.8.1 Shanxi Huakang Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Shanxi Huakang Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Shanxi Huakang Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  48. 8.8.5 Shanxi Huakang Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd.
  50. 8.9.1 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  54. 8.9.5 Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.
  56. 8.10.1 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  60. 8.10.5 Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Mayinglong Pharmaceutical Group Co., Ltd.
  62. 8.11.1 Mayinglong Pharmaceutical Group Co., Ltd. Company Information
  63. 8.11.2 Mayinglong Pharmaceutical Group Co., Ltd. Business Overview
  64. 8.11.3 Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Mayinglong Pharmaceutical Group Co., Ltd. Vascular Protective Agents Product Portfolio
  66. 8.11.5 Mayinglong Pharmaceutical Group Co., Ltd. Recent Developments
  67. 8.12 Jilin Jinsheng Pharmaceutical Co., Ltd.
  68. 8.12.1 Jilin Jinsheng Pharmaceutical Co., Ltd. Company Information
  69. 8.12.2 Jilin Jinsheng Pharmaceutical Co., Ltd. Business Overview
  70. 8.12.3 Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Jilin Jinsheng Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  72. 8.12.5 Jilin Jinsheng Pharmaceutical Co., Ltd. Recent Developments
  73. 8.13 Hunan Yige Pharmaceutical Co., Ltd.
  74. 8.13.1 Hunan Yige Pharmaceutical Co., Ltd. Company Information
  75. 8.13.2 Hunan Yige Pharmaceutical Co., Ltd. Business Overview
  76. 8.13.3 Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Hunan Yige Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  78. 8.13.5 Hunan Yige Pharmaceutical Co., Ltd. Recent Developments
  79. 8.14 Hubei Keyi Pharmaceutical Co., Ltd.
  80. 8.14.1 Hubei Keyi Pharmaceutical Co., Ltd. Company Information
  81. 8.14.2 Hubei Keyi Pharmaceutical Co., Ltd. Business Overview
  82. 8.14.3 Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Hubei Keyi Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  84. 8.14.5 Hubei Keyi Pharmaceutical Co., Ltd. Recent Developments
  85. 8.15 Guangxi Hercules Pharmaceutical Co., Ltd.
  86. 8.15.1 Guangxi Hercules Pharmaceutical Co., Ltd. Company Information
  87. 8.15.2 Guangxi Hercules Pharmaceutical Co., Ltd. Business Overview
  88. 8.15.3 Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Guangxi Hercules Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  90. 8.15.5 Guangxi Hercules Pharmaceutical Co., Ltd. Recent Developments
  91. 8.16 Chengdu Yazhong Biopharmaceutical Co., Ltd.
  92. 8.16.1 Chengdu Yazhong Biopharmaceutical Co., Ltd. Company Information
  93. 8.16.2 Chengdu Yazhong Biopharmaceutical Co., Ltd. Business Overview
  94. 8.16.3 Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Chengdu Yazhong Biopharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  96. 8.16.5 Chengdu Yazhong Biopharmaceutical Co., Ltd. Recent Developments
  97. 8.17 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd.
  98. 8.17.1 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Company Information
  99. 8.17.2 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Business Overview
  100. 8.17.3 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Vascular Protective Agents Product Portfolio
  102. 8.17.5 Changzhou Qianhong Biochemical Pharmaceutical Co., Ltd. Recent Developments
  103. 8.18 STELLA
  104. 8.18.1 STELLA Company Information
  105. 8.18.2 STELLA Business Overview
  106. 8.18.3 STELLA Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 STELLA Vascular Protective Agents Product Portfolio
  108. 8.18.5 STELLA Recent Developments
  109. 8.19 Stanex
  110. 8.19.1 Stanex Company Information
  111. 8.19.2 Stanex Business Overview
  112. 8.19.3 Stanex Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Stanex Vascular Protective Agents Product Portfolio
  114. 8.19.5 Stanex Recent Developments
  115. 8.20 Sebela Pharmaceuticals Inc.
  116. 8.20.1 Sebela Pharmaceuticals Inc. Company Information
  117. 8.20.2 Sebela Pharmaceuticals Inc. Business Overview
  118. 8.20.3 Sebela Pharmaceuticals Inc. Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Sebela Pharmaceuticals Inc. Vascular Protective Agents Product Portfolio
  120. 8.20.5 Sebela Pharmaceuticals Inc. Recent Developments
  121. 8.21 Pfizer
  122. 8.21.1 Pfizer Company Information
  123. 8.21.2 Pfizer Business Overview
  124. 8.21.3 Pfizer Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Pfizer Vascular Protective Agents Product Portfolio
  126. 8.21.5 Pfizer Recent Developments
  127. 8.22 Manus Aktteva Biopharma LLP
  128. 8.22.1 Manus Aktteva Biopharma LLP Company Information
  129. 8.22.2 Manus Aktteva Biopharma LLP Business Overview
  130. 8.22.3 Manus Aktteva Biopharma LLP Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Manus Aktteva Biopharma LLP Vascular Protective Agents Product Portfolio
  132. 8.22.5 Manus Aktteva Biopharma LLP Recent Developments
  133. 8.23 Hepac
  134. 8.23.1 Hepac Company Information
  135. 8.23.2 Hepac Business Overview
  136. 8.23.3 Hepac Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Hepac Vascular Protective Agents Product Portfolio
  138. 8.23.5 Hepac Recent Developments
  139. 8.24 Globela Pharma
  140. 8.24.1 Globela Pharma Company Information
  141. 8.24.2 Globela Pharma Business Overview
  142. 8.24.3 Globela Pharma Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Globela Pharma Vascular Protective Agents Product Portfolio
  144. 8.24.5 Globela Pharma Recent Developments
  145. 8.25 Bioiberica
  146. 8.25.1 Bioiberica Company Information
  147. 8.25.2 Bioiberica Business Overview
  148. 8.25.3 Bioiberica Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Bioiberica Vascular Protective Agents Product Portfolio
  150. 8.25.5 Bioiberica Recent Developments
  151. 8.26 Advacare Pharma
  152. 8.26.1 Advacare Pharma Company Information
  153. 8.26.2 Advacare Pharma Business Overview
  154. 8.26.3 Advacare Pharma Vascular Protective Agents Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Advacare Pharma Vascular Protective Agents Product Portfolio
  156. 8.26.5 Advacare Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Vascular Protective Agents Value Chain Analysis
  2. 9.1.1 Vascular Protective Agents Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Vascular Protective Agents Production Mode & Process
  6. 9.2 Vascular Protective Agents Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Vascular Protective Agents Distributors
  9. 9.2.3 Vascular Protective Agents Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst